Healthcare provider profile · identity verified

Edward J Malone, MD

Family Practice · LA CROSSE, WI · NPI 1194786673

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	223	49
Omeprazole	Omeprazole	187	43
Levothyroxine Sodium	Levothyroxine Sodium	178	31
Lisinopril	Lisinopril	145	31
Amlodipine Besylate	Amlodipine Besylate	125	29
Metoprolol Succinate	Metoprolol Succinate	120	33
Losartan Potassium	Losartan Potassium	114	27
Duloxetine Hcl	Duloxetine Hcl	94	16
Tamsulosin Hcl	Tamsulosin Hcl	94	20
Gabapentin	Gabapentin	86	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	85	11
Quetiapine Fumarate	Quetiapine Fumarate	80	suppressed
Furosemide	Furosemide	75	17
Jardiance	Empagliflozin	72	11
Oxycodone Hcl	Oxycodone Hcl	70	13
Clonazepam	Clonazepam	64	suppressed
Eliquis	Apixaban	64	suppressed
Bupropion Xl	Bupropion Hcl	62	11
Metformin Hcl	Metformin Hcl	60	11
Simvastatin	Simvastatin	57	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	56	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	53	13
Montelukast Sodium	Montelukast Sodium	52	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	50	12
Venlafaxine Hcl Er	Venlafaxine Hcl	50	suppressed
Famotidine	Famotidine	47	suppressed
Tizanidine Hcl	Tizanidine Hcl	45	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	44	19
Ozempic	Semaglutide	42	suppressed
Allopurinol	Allopurinol	41	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	41	13
Mirtazapine	Mirtazapine	41	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	39	12
Pregabalin	Pregabalin	38	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	37	suppressed
Finasteride	Finasteride	36	suppressed
Trazodone Hcl	Trazodone Hcl	36	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	suppressed
Carvedilol	Carvedilol	34	suppressed
Divalproex Sodium	Divalproex Sodium	34	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	34	suppressed
Lorazepam	Lorazepam	32	suppressed
Potassium Chloride	Potassium Chloride	31	suppressed
Propranolol Hcl	Propranolol Hcl	29	suppressed
Sertraline Hcl	Sertraline Hcl	29	suppressed
Ventolin Hfa	Albuterol Sulfate	28	suppressed
Prednisone	Prednisone	27	11
Butorphanol Tartrate	Butorphanol Tartrate	26	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	26	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Metformin Hcl Er	Metformin Hcl	26	suppressed
Spironolactone	Spironolactone	26	suppressed
Trulicity	Dulaglutide	26	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	25	suppressed
Hydrocortisone	Hydrocortisone	25	suppressed
Tramadol Hcl	Tramadol Hcl	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	24	suppressed
Oxycontin	Oxycodone Hcl	24	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	21	suppressed
Atenolol	Atenolol	20	suppressed
Baclofen	Baclofen	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Propranolol Hcl Er	Propranolol Hcl	20	suppressed
Divalproex Sodium Er	Divalproex Sodium	19	suppressed
Glipizide Er	Glipizide	19	suppressed
Aripiprazole	Aripiprazole	17	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	suppressed
Mounjaro	Tirzepatide	17	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	17	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	16	suppressed
Diltiazem Hcl	Diltiazem Hcl	16	suppressed
Fluconazole	Fluconazole	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	15	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Torsemide	Torsemide	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Celecoxib	Celecoxib	13	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	13	suppressed
Klor-Con M20	Potassium Chloride	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Nabumetone	Nabumetone	13	suppressed
Nexium	Esomeprazole Magnesium	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Otezla	Apremilast	13	suppressed
Prazosin Hcl	Prazosin Hcl	13	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Digoxin	Digoxin	12	suppressed
Fluticasone Propionate	Fluticasone Propionate	12	suppressed
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	suppressed
Morphine Sulfate Er	Morphine Sulfate	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Cefdinir	Cefdinir	11	suppressed
Loperamide	Loperamide Hcl	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Valsartan	Valsartan	11	suppressed
Xifaxan	Rifaximin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error